Heartflow, Inc. (NASDAQ:HTFL) Receives Average Recommendation of “Moderate Buy” from Analysts

Heartflow, Inc. (NASDAQ:HTFL) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $37.6667.

HTFL has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Canaccord Genuity Group upped their price target on Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. lowered their target price on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Wells Fargo & Company decreased their price objective on shares of Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday.

Insider Transactions at Heartflow

In related news, insider Campbell Rogers sold 65,153 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $24.49, for a total transaction of $1,595,596.97. Following the completion of the transaction, the insider owned 76,034 shares in the company, valued at approximately $1,862,072.66. This represents a 46.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John C.M. Farquhar sold 9,725 shares of the business’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $25.00, for a total transaction of $243,125.00. Following the sale, the chief executive officer directly owned 571,725 shares in the company, valued at $14,293,125. This trade represents a 1.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 2,127,399 shares of company stock worth $59,295,771 in the last 90 days.

Institutional Investors Weigh In On Heartflow

Several large investors have recently made changes to their positions in the stock. XXEC Inc. increased its holdings in Heartflow by 40.5% during the fourth quarter. XXEC Inc. now owns 41,920 shares of the company’s stock worth $1,222,000 after buying an additional 12,088 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Heartflow in the fourth quarter valued at $72,000. Invesco Ltd. grew its position in shares of Heartflow by 463.9% in the 4th quarter. Invesco Ltd. now owns 577,397 shares of the company’s stock valued at $16,831,000 after acquiring an additional 475,004 shares during the period. XTX Topco Ltd grew its position in shares of Heartflow by 282.6% in the 4th quarter. XTX Topco Ltd now owns 43,205 shares of the company’s stock valued at $1,259,000 after acquiring an additional 31,913 shares during the period. Finally, VARCOV Co. bought a new stake in Heartflow in the fourth quarter valued at approximately $1,657,000.

Key Stories Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong top‑line growth — HeartFlow reported revenue of $49.13M vs consensus $46.58M, up ~40.5% year‑over‑year, signaling accelerating adoption and top-line momentum. MarketBeat: Q4 results & transcript
• Positive Sentiment: Bullish analyst move — Canaccord raised its price target to $43 and maintained a Buy rating, implying a sizable upside and providing supportive institutional sentiment. Benzinga: Canaccord price target raise
• Neutral Sentiment: Analysts cut targets but stayed positive — JPMorgan lowered its PT from $40 to $35 but kept an Overweight rating, signaling confidence in the business even while trimming valuation assumptions. Benzinga: JPMorgan PT change
• Neutral Sentiment: Wells Fargo also trimmed its PT (from $38 to $35) but maintained an Overweight rating, another sign of cautious optimism. Benzinga: Wells Fargo PT change
• Neutral Sentiment: Independent analysis available — Seeking Alpha published a piece reviewing HeartFlow’s strategy and growth opportunities; useful for investors analyzing the longer‑term thesis. Seeking Alpha: HeartFlow: Getting Into The Flow
• Negative Sentiment: EPS miss and continued losses — HeartFlow reported GAAP EPS of ($0.29) vs consensus ($0.16), missing estimates and underscoring margin pressure and ongoing unprofitability (PE remains negative). MarketBeat: EPS miss / earnings details
• Negative Sentiment: Valuation and trend considerations — Despite the rally, the stock remains below its 50‑day and 200‑day moving averages and carries a wide range of analyst targets, indicating continued volatility and mixed near‑term sentiment. Benzinga: HTFL earnings & estimates

Heartflow Trading Up 0.5%

NASDAQ HTFL opened at $26.02 on Friday. Heartflow has a 1-year low of $20.13 and a 1-year high of $41.22. The company has a market capitalization of $2.23 billion and a price-to-earnings ratio of -14.38. The stock’s 50 day moving average is $26.86 and its two-hundred day moving average is $30.41.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.